线粒体DNA异质性在肝细胞癌中的研究进展

肝脏 ›› 2025, Vol. 30 ›› Issue (10): 1306-1308.

线粒体DNA异质性在肝细胞癌中的研究进展

纪留娟, 沈银忠

201508 上海上海市公共卫生临床中心重症肝病科(纪留娟),感染与免疫科(沈银忠)

收稿日期:2025-09-24 出版日期:2025-10-31 发布日期:2025-12-16
通讯作者: 沈银忠,Email: shenyinzhong@fudan.edu.cn
基金资助:
2024年度上海市市级医院诊疗技术推广及优化管理项目(项目编号:SHDC22024317)

Received:2025-09-24 Online:2025-10-31 Published:2025-12-16

摘要/Abstract

摘要： 肝细胞癌(HCC)是一种致死率极高的恶性肿瘤,其瘤内异质性(ITH)与肿瘤增殖、侵袭特性及治疗抵抗密切相关,是影响患者临床预后的关键因素。线粒体 DNA(mtDNA)体细胞突变在 HCC 中普遍存在,细胞内突变型与野生型mtDNA共存的异质性状态具有明显的细胞间差异,可调控肿瘤的发生、发展进程。本文系统综述了 mtDNA 异质性在 HCC 发生、发展中的作用机制,对基于 mtDNA 的 HCC 治疗策略进行总结,以期为 HCC 临床诊疗提供新的理论依据,并为 mtDNA 靶向治疗的未来研究方向提供参考。

关键词: 线粒体DNA异质性, 肝细胞癌, 作用机制, 靶向治疗

纪留娟, 沈银忠. 线粒体DNA异质性在肝细胞癌中的研究进展[J]. 肝脏, 2025, 30(10): 1306-1308.

/ 推荐

参考文献

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024,74(3): 229-263.
[2] Zheng R S, Chen R, Han B F, et al. Cancer incidence and mortality in China, 2022[J]. Zhonghua Zhong Liu Za Zhi, 2024,46(3): 221-231.
[3] Llovet J M, Pinyol R, Yarchoan M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2024,21(4): 294-311.
[4] Yang Q, Cui M, Wang J, et al. Circulating mitochondrial DNA promotes M2 polarization of tumor associated macrophages and HCC resistance to sorafenib[J]. Cell Death Dis, 2025,16(1): 153.
[5] Dhanasekaran R, Suzuki H, Lemaitre L, et al. Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making[J]. Hepatology, 2025,81(3): 1038-1057.
[6] Kopinski P K, Singh L N, Zhang S, et al. Mitochondrial DNA variation and cancer[J]. Nat Rev Cancer, 2021,21(7): 431-445.
[7] Newman L E, Weiser N S, Rojas G R, et al. Mitochondrial DNA replication stress triggers a pro-inflammatory endosomal pathway of nucleoid disposal[J]. Nat Cell Biol, 2024,26(2): 194-206.
[8] Shibata T, Hoshida Y. Mitochondrial genome diversity drives heterogeneity in HCC[J]. Hepatology, 2025,82(1): 12-13.
[9] Fu J, Liu Q, YUAN Y, et al. Mitochondrial DNA-mediated intercellular communication via extracellular vesicles under hypoxic stress to drive HCC progression[J]. Cancer Sci, 2025.
[10] Gupta R, Kanai M, Durham T J, et al. Nuclear genetic control of mtDNA copy number and heteroplasmy in humans[J]. Nature, 2023,620(7975): 839-848.
[11] Zhou K, Wang Z, Guo W, et al. Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution[J]. Hepatology, 2025,82(1): 59-76.
[12] Yang L Y, Shen X T, Sun H T, et al. Neutrophil extracellular traps in hepatocellular carcinoma are enriched in oxidized mitochondrial DNA which is highly pro-inflammatory and pro-metastatic[J]. J Cancer, 2022,13(4): 1261-1271.
[13] Yin C, Li D Y, Guo X, et al. NGS-based profiling reveals a critical contributing role of somatic D-loop mtDNA mutations in HBV-related hepatocarcinogenesis[J]. Ann Oncol, 2019,30(6): 953-962.
[14] Guo Z S, Jin C L, Yao Z J, et al. Analysis of the mitochondrial 4977 bp deletion in patients with hepatocellular carcinoma[J]. Balkan J Med Genet, 2017,20(1): 81-86.
[15] Shidoji Y. Induction of hepatoma cell pyroptosis by endogenous lipid geranylgeranoic acid-a comparison with palmitic acid and retinoic acid[J]. Cells, 2024,13(10).
[16] Hou Z L, Han F Y, Lou L L, et al. The nature compound dehydrocrenatidine exerts potent antihepatocellular carcinoma by destroying mitochondrial complexes in vitro and in vivo[J]. Phytother Res, 2022,36(3): 1353-1371.
[17] Zhao J, Cui M, Yao X, et al. Targeting TFAM downregulation mediated mtDNA-NLRP3 pathway suppresses TAM infiltration and HCC progression[J]. Oncogene, 2025,44(33): 2956-2969.
[18] Huang Q, Wu D, Zhao J, et al. TFAM loss induces nuclear actin assembly upon mDia2 malonylation to promote liver cancer metastasis[J]. EMBO J, 2022,41(11): e110324.
[19] Wen J, Zhang X, Wong C C, et al. Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma[J]. Gut, 2024,73(12): 2023-2036.
[20] Li Q, Chen Q, Yang X, et al. Cocktail strategy based on a dual function nanoparticle and immune activator for effective tumor suppressive[J]. J Nanobiotechnology, 2022,20(1): 84.
[21] Hu H, Zhang F, Sheng Z, et al. Synthesis and mitochondria-localized iridium (III) complexes induce cell death through pyroptosis and ferroptosis pathways[J]. Eur J Med Chem, 2024,268: 116295.
[22] Tan G, Hou G, Qian J, et al. Hyaluronan-decorated copper-doxorubicin-anlotinib nanoconjugate for targeted synergistic chemo/chemodynamic/antiangiogenic tritherapy against hepatocellular carcinoma[J]. J Colloid Interface Sci, 2024,662: 857-869.
[23] Tang J, Du K. Mitochondrial base editing: from principle, optimization to application[J]. Cell Biosci, 2025,15(1): 9.
[24] Mok B Y, de Moraes M H, Zeng J, et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing[J]. Nature, 2020,583(7817): 631-637.